Augmented expression of tumour necrosis factor-α and lymphotoxin in mononuclear cells in multiple sclerosis and optic neuritis

Brain

Volumn 119, Issue 1, 1996, Pages 213-223

  Navikas, V ^a   He, B ^a   Link, J ^a   Haglund, M ^a   Soderstrom M ^a   Fredrikson, S ^a   Ljungdahl, A ^a   Hojeberg B ^a   Qiao, J ^a   Olsson, T ^a   Link, H ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Autoimmunity; Cytokines; Lymphotoxin; Multiple sclerosis; Tumour necrosis factor

Indexed keywords

COMPLEMENTARY DNA; GAMMA INTERFERON; LYMPHOTOXIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; ASEPTIC MENINGITIS; CONTROLLED STUDY; FEMALE; HUMAN; IN SITU HYBRIDIZATION; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; OLIGONUCLEOTIDE PROBE; OPTIC NERVE DISEASE; PRIORITY JOURNAL;

ADULT; AGED; CELLS, CULTURED; CEREBROSPINAL FLUID; DNA PROBES; FEMALE; HUMANS; IN SITU HYBRIDIZATION; LYMPHOTOXIN-ALPHA; MALE; MIDDLE AGED; MONOCYTES; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEINS; OPTIC NEURITIS; REFERENCE VALUES; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 13344278688     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/119.1.213     Document Type: Article

References (51)

1. Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand 1988; 78: 318-23.
2. Beutler B, Cerami A. The biology of cachectin/TNF - a primary mediator of the host response. [Review]. Annu Rev Immunol 1989; 7: 625-55.
3. Brideau RJ, Carter PB, McMaster WR, Mason DW, Williams AF. Two subsets of rat T lymphocytes defined with monoclonal antibodies. Eur J Immunol 1980; 10: 609-15.
4. Chung IY, Norris JG, Benveniste EN. Differential tumor necrosis factor α expression by astrocytes from experimental allergic encephalomyelitis-susceptible and -resistant rat strains. J Exp Med 1991; 173: 801-11.
5. Collart MA, Belin D, Vassalli JD, de Kossodo S, Vassalli P. Gamma-interferon enhances macrophage transcription of the tumor necrosis factor/cachectin, interleukin I, and urokinase genes, which are controlled by short-lived repressors. J Exp Med 1986; 164: 2113-18.
6. Dagerlind Å, Friberg K, Bean AJ, Hökfelt T. Sensitive mRNA detection using unfixed tissue: combined radioactive and nonradioactive in situ hybridization histochemistry. Histochemistry 1992; 98: 39-49.
7. Deibler GE, Martenson RE, Kies MW. Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species. Prep Biochem 1972; 2: 139-65.
8. ElGhazali GEB, Paulie S, Andersson G, Hansson Y, Holmquist G, Sun JB, et al. Number of interleukin-4 and interferon-gamma-secreting human T cells reactive with tetanus toxoid and the mycobacterial antigen PPD or phytohemagglutinin: distinct response profiles depending on the type of antigen used for activation. Eur J Immunol 1993; 23: 2740-5.
9. Franciotta DM, Grimaldi LME, Martino GV, Piccolo G, Bergamaschi R, Citterio A, et al. Tumor necrosis factor in serum and cerebrospinal fluid of patients with multiple sclerosis. Ann Neurol 1989; 26: 787-9.
10. Gallo P, Piccinno MG, Krzalic L, Tavolato B. Tumor necrosis factor alpha (TNF-α) and neurological diseases. Failure in detecting TNF-α in the cerebrospinal fluid from patients with multiple sclerosis, AIDS dementia complex, and brain tumours. J Neuroimmunol 1989; 23: 41-1.
11. Gray PW, Aggarwal BB, Benton CV, Bringman TS, Henzel WJ, Jarrett JA, et al. Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity. Nature 1984; 312: 721-1.
12. Hauser SL, Doolittle TH, Lincoln R, Brown RH, Dinarello CA. Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6. Neurology 1990; 40: 1735-9.
13. Held W, Meyermann R, Qin Y, Mueller C. Perform and tumor necrosis factor α in the pathogenesis of experimental allergic encephalomyelitis: comparison of autoantigen induced and transferred disease in Lewis rats. J Autoimmun 1993; 6: 311-22.
14. Hofman FM, Hinton DR, Johnson K, Merrill JE. Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 1989; 170: 607-12.
15. Holmdahl R, Andersson M, Tarkowski A. Origin of the autoreactive anti-type II collagen response. I. Frequency of specific and multispecific B cells in primed murine lymph nodes. Immunology 1987; 61: 369-74.
16. Kamijo R, Le J, Shapiro D, Havell EA, Huang S, Aguet M, et al. Mice that lack the interferon-gamma receptor have profoundly altered responses to infection with Bacillus Calmette-Guerin and subsequent challenge with lipopolysaccharide. J Exp Med 1993; 178: 1435-40.
17. Khoury SJ, Hancock WW, Weiner HL. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor β, interleukin 4, and prostaglandin E expression in the brain. J Exp Med 1992; 176: 1355-64.
18. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
19. Lieberman AP, Pitha PM, Shin HS, Shin ML. Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. Proc Natl Acad Sci USA 1989; 86: 6348-52.
20. Link J, Söderström M, Olsson T, Höjeberg B, Ljungdahl Å, Link H. Increased transforming growth factor-β, interleukin-4 and interferon-γ in multiple sclerosis. Ann Neurol 1994a; 36: 379-86.
21. Link J, Söderström M, Kostulas V, Olsson T, Höjeberg B, Ljungdahl Å, et al. Optic neuritis is associated with myelin basic protein and proteolipid protein reactive cells producing interferon-γ, interleukin-4 and transforming growth factor-β. J Neuroimmunol 1994b; 49: 9-18.
22. Lu C-Z, Jensen MA, Arnason BGW. Interferon-γ and interleukin-4 secreting cells in multiple sclerosis. J Neuroimmunol 1993; 46: 123-8.
23. Maimone D, Gregory S, Arnason BGW, Reder AT. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol 1991; 32: 67-74.
24. Navikas V, Link J, Palasik W, Söderström M, Fredrikson S, Olsson T, et al. Increased mRNA expression of IL-10 in mononuclear cells in multiple sclerosis and optic neuritis. Scand J Immunol 1995; 41: 171-8.
25. Noseworthy JH, Rodriguez M, Jiang N-S, Sneve DM, Carter JL, Shuster EA, et al. TNF-alpha in multiple sclerosis [abstract]. Neurology 1993; 43 (4 Suppl 2): A355.
26. Olsson T, Kostulas V, Link H. Improved detection of oligoclonal IgG in cerebrospinal fluid by isoelectric focusing in agarose, double-antibody peroxidase labelling, and avidin-biotin amplification. Clin Chem 1984; 30: 1246-9.
27. Olsson T, Zhi WW, Höjeberg B, Kostulas V, Jiang YP, Anderson G, et al. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-γ. J Clin Invest 1990; 86: 981-5.
28. Pennica D, Nedwin GE, Hayflick JS, Seeburg PH, Derynck R, Palladino MA, et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984; 312: 724-9.
29. Peter JB, Boctor FN, Tourtellotte WW. Serum and CSF levels of IL-2, sIL-2R, TNF-α, and IL-1β in chronic progressive multiple sclerosis: expected lack of clinical utility. Neurology 1991; 41: 121-3.
30. Powell MB, Mitchell D, Lederman J, Buckmeier J, Zamvil SS, Graham M, et al. Lymphotoxin and tumor necrosis factor-alpha production by myelin basic protein-specific T cell clones correlates with encephalitogenicity. Int Immunol 1990; 2: 539-44.
31. Rieckmann P, Albrecht M, Kitze B, Weber T, Tumani H, Broocks A, et al. Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology 1994; 44: 1523-6.
32. Rieckmann P, Albrecht M, Kitze B, Weber T, Tumani H, Broocks A, et al. Tumor necrosis factor-a messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 1995; 37: 82-8.
33. Ruddle NH. Tumour necrosis factor-beta/Lymphotoxin-alpha. In: Thomson AW, editor. The cytokine handbook. 2nd ed. London Academic Press, 1994: 305-18.
34. Ruddle NH, Schmid DS. The role of lymphotoxin in T-cell-mediated cytotoxicity. Ann Inst Pasteur Immunol 1987; 138: 314-20.
35. Ruddle NH, Bergman CM, McGrath KM, Lingenheld EG, Grunnet ML, Padula SJ, et al. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med 1990; 172: 1193-200.
36. Schumacher GA, Beebe G, Kibler RF, Kurland LT, Kurtzke JF, McDowell F, et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci 1965; 122: 552-68.
37. Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988; 23: 339-46.
38. Selmaj K, Raine CS, Cannella B, Brosnan CF. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 1991a; 87: 949-54.
39. Selmaj K, Raine CS, Farooq M, Norton WT, Brosnan CF. Cytokine cytotoxicity against oligodendrocytes: apoptosis induced by lymphotoxin. J Immunol 1991b; 147: 1522-9.
40. Selmaj K, Raine CS, Cross AH. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann Neurol 1991c; 30: 694-700.
41. Sharief MK, Hentges R. Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis [see comments]. N Engl J Med 1991; 325: 467-72. Comment in: N Engl J Med 1992; 326: 272-3.
42. Sharief MK, Hentges R. Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis [see comments]. N Engl J Med 1991; 325: 467-72. Comment in: N Engl J Med 1992; 326: 272-3.
43. Sharief MK, Thompson EJ. In vivo relationship of tumor necrosis factor-α to blood-brain barrier damage in patients with active multiple sclerosis. J Neuroimmunol 1992; 38: 27-34.
44. Shaw CE, Dunbar PR, Macaulay HA, Neale TJ. Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol 1995; 242: 53-8.
45. Söderström M, Lindqvist M, Hillert J, Käll TB, Link H. Optic neuritis: findings on MRI, CSF examination and HLA class II typing in 60 patients and results of a short-term follow-up. J Neurol 1994; 241: 391-7.
46. Sun JB, Olsson T, Wang W-Z, Xiao B-G, Kostulas V, Fredrikson S, et al. Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls. Eur J Immunol 1991; 21: 1461-8.
47. Tibbling G, Link H, Öhman S. Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest 1977; 37: 385-90.
48. Tracey KJ. Tumour necrosis factor-alpha. In: Thomson AW, editor. The cytokine handbook. 2nd ed. London: Academic Press, 1994: 289-304.
49. Tsukada N, Miyagi K, Matsuda M, Yanagisawa N, Yone K. Tumor necrosis factor and interleukin-1 in the CSF and sera of patients with multiple sclerosis. J Neurol Sci 1991; 104: 230-4.
50. Vassalli P. The pathophysiology of tumor necrosis factors. [Review]. Annu Rev Immunol 1992; 10: 411-52.
51. Wang Z-Y, Qiao J, Link H. Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor. J Neuroimmunol 1993; 44: 209-14.